Patent intelligence · US
US 10905692
Combination therapy for treating malignancies
Combination therapy for treating malignancies
Patent details — US 10905692
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 2, 2021
- Expiration
- Jan 28, 2041
- Applicant
- Agios Pharmaceuticals, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K2300/00, A61K31/136, A61K31/53
Quick answer
US 10905692 (Combination therapy for treating malignancies) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Feb 2, 2021. Expires Jan 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Agios Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K2300/00, A61K31/136, A61K31/53, A61K31/704, A61K31/7048
More from Agios Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428376
Therapeutic compounds and compositions
granted -
US 12377093
Pyruvate kinase activators for use in therapy
granted -
US 12133853
Pyruvate kinase activators for use in treating blood disorders
granted -
US 11957680
Pyruvate kinase activators for use in treating blood disorders
granted -
US 11919915
Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
granted -
US 11878049
Mitapivat therapy and modulators of cytochrome P450
granted -
US 11872225
Pyruvate kinase modulators and use thereof
granted -
US 11866411
Therapeutic compounds and compositions
granted
Frequently asked questions
What is US patent 10905692?
US 10905692 (Combination therapy for treating malignancies) is held by Agios Pharmaceuticals, Inc.. Status: granted. Granted Feb 2, 2021. Expires Jan 28, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10905692?
Agios Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.
When does US 10905692 expire?
Our index shows an expiration date of Jan 28, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.